Skip to main content

Kerri Fitzgerald

11/14/2014
“[Specialty pharmacy] is front page news today,” said Jim Smeeding, RPh, MBA, executive director, NASP, as he opened a session on current trends and future outlooks on the specialty pharmacy industry.
“[Specialty pharmacy] is front page news today,” said Jim Smeeding, RPh, MBA, executive director, NASP, as he opened a session on current trends and future outlooks on the specialty pharmacy industry.
“[Specialty pharmacy] is front...
11/14/2014
First Report Managed Care
01/20/2014
As need for emergency services and costs continue to rise, patients at EDs face long waits and medical professionals find themselves weighed down by overcrowding.
As need for emergency services and costs continue to rise, patients at EDs face long waits and medical professionals find themselves weighed down by overcrowding.
As need for emergency services...
01/20/2014
First Report Managed Care
News Connection
04/22/2014
For chronic conditions, patient health education can reduce mortality and morbidly, in part due to self-managing tasks and understanding of proper medication use. Previous studies have indicated that health professionals sometimes fail to...
For chronic conditions, patient health education can reduce mortality and morbidly, in part due to self-managing tasks and understanding of proper medication use. Previous studies have indicated that health professionals sometimes fail to...
For chronic conditions, patient...
04/22/2014
First Report Managed Care
07/22/2014
Four years after the Patient Protection and Affordable Care Act (ACA) was passed and just months into the first year of healthcare exchanges, 6 in 10 Americans (60%) said they feel no direct personal impact of the law, according to a survey...
Four years after the Patient Protection and Affordable Care Act (ACA) was passed and just months into the first year of healthcare exchanges, 6 in 10 Americans (60%) said they feel no direct personal impact of the law, according to a survey...
Four years after the Patient...
07/22/2014
First Report Managed Care
Feature
03/21/2011
In a head-to-head study, researchers found that compared with losartan, candesartan is associated with lower all-cause mortality in patients with heart failure (HF). In a study presented in the Journal of the American Medical Association...
In a head-to-head study, researchers found that compared with losartan, candesartan is associated with lower all-cause mortality in patients with heart failure (HF). In a study presented in the Journal of the American Medical Association...
In a head-to-head study,...
03/21/2011
First Report Managed Care
02/17/2015
As the US population continues to age, questions arise regarding Medicare costs and implications for the federal budget.
As the US population continues to age, questions arise regarding Medicare costs and implications for the federal budget.
As the US population continues...
02/17/2015
First Report Managed Care
05/21/2014
Tampa—The specialty pharmacy market is going to see increased competition and a number of orphan drug and breakthrough therapy approvals in the near future, according to Aimee Tharaldson, PharmD, senior clinic consultant, emerging...
Tampa—The specialty pharmacy market is going to see increased competition and a number of orphan drug and breakthrough therapy approvals in the near future, according to Aimee Tharaldson, PharmD, senior clinic consultant, emerging...
Tampa—The specialty pharmacy...
05/21/2014
First Report Managed Care
Conference Insider
12/18/2013
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial assessed ST-elevation myocardial infarction patients.
The Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial assessed ST-elevation myocardial infarction patients.
The Strategic Reperfusion Early...
12/18/2013
First Report Managed Care
11/14/2014
Once again, HCV is at the forefront of discussions as the FDA just recently approved the first once-daily oral combination of ledipasvir and sofosbuvir to treat HCV genotype 1 infection, which comes with an even larger pricetag: $94,500 for a...
Once again, HCV is at the forefront of discussions as the FDA just recently approved the first once-daily oral combination of ledipasvir and sofosbuvir to treat HCV genotype 1 infection, which comes with an even larger pricetag: $94,500 for a...
Once again, HCV is at the...
11/14/2014
First Report Managed Care
12/18/2013
For patients with heart failure and preserved left ventricular ejection fraction (HFpEF), there is no proven therapy to improve the prognosis.
For patients with heart failure and preserved left ventricular ejection fraction (HFpEF), there is no proven therapy to improve the prognosis.
For patients with heart failure...
12/18/2013
First Report Managed Care